Medication treatment for opioid use disorder in expectant mothers (MOMs): Design considerations for a pragmatic randomized trial comparing extended-release and daily buprenorphine formulations

Opioid use disorder (OUD) in pregnant women has increased significantly in recent years. Maintaining these women on sublingual (SL) buprenorphine (BUP) is an evidence-based practice but BUP-SL is associated with several disadvantages that an extended-release (XR) BUP formulation could eliminate. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Winhusen, Theresa, Lofwall, Michelle, Jones, Hendrée E., Wilder, Christine, Lindblad, Robert, Schiff, Davida M., Wexelblatt, Scott, Merhar, Stephanie, Murphy, Sean M., Greenfield, Shelly F., Terplan, Mishka, Wachman, Elisha M., Kropp, Frankie, Theobald, Jeff, Lewis, Mitra, Matthews, Abigail G., Guille, Connie, Silverstein, Michael, Rosa, Carmen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7184985/
https://www.ncbi.nlm.nih.gov/pubmed/32353544
http://dx.doi.org/10.1016/j.cct.2020.106014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7184985/
https://www.ncbi.nlm.nih.gov/pubmed/32353544
http://dx.doi.org/10.1016/j.cct.2020.106014

Ejemplares similares